A Randomized,Double-blind, Placebo Controlled, Multicenter Study to

Status Recruiting

Clinical Trial Summary

The goal of this randomized, double-blind, placebo controlled, Multicenter Phase II clinical trial is to initially evaluate the Safety and Efficacy of MT2004 Capsule in Cholestatic and Mixed drug induced liver injury (DILI) subjects. The main questions it aims to answer are: 1. The Efficacy of MT2004 Capsule in Cholestatic and Mixed DILI subjects 2. The Safety and Pharmacokinetic characteristic of MT2004 Capsule in Cholestatic and Mixed DILI subjects 3. The mechanism of using MT2004 Capsule on Cholestatic and Mixed DILI subjects

Clinical Trial Description

Xi'An Aolitai Pharmaceutical Technology Co Ltd is developing MT2004, a novel investigational synthetic small molecule farnesoid X receptor (FXR) agonist targeted to the liver. The MT2004 was designed as the prodrug and the metabolites MT2004-met1 of MT2004 will act to the FXR receptor to regulate a series of genes expression. It also plays an important role in the metabolism of bile acids, lipids and sugars. The goal of this randomized, double-blind, placebo controlled, Multicenter Phase II clinical trial is to initially evaluate the Safety and Efficacy of MT2004 Capsule in Cholestatic and Mixed drug induced liver injury (DILI) subjects. The whole study will be divied to three stages including screening period (14 Days before the treatment), treatment period (the participants will be randomized to receive MT2004, or placebo orally (BID), for 12 weeks) and follow-up period. The study aims to recruit total of 80 subjects with Cholestatic and Mixed DILI, in which 12 of subjects will be firstly enrolled and allocated to the MT2004 group (Dose level: 25mg) as well as control group with the proportion of 2:1 by using the stratified randomization method. During the whole study, the adjustment of the subjects amount, the dose level as well as randomization proportion will based on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID. The placebo will be used in this study, and the researchers will compare the placebo and test article to see the safety and efficacy. ;

Study Design

Related Conditions & MeSH terms

Chemical and Drug Induced Liver Injury
Drug-Induced Liver Injury
Wounds and Injuries

Clinical Trial Details

NCT number	NCT06019936
Study type	Interventional
Source	Shaanxi Micot Technology Limited Company
Contact	LanLan Song, Master
Phone	+8615929300901
Email	songlanlan@micot.cn
Status	Recruiting
Phase	Phase 2
Start date	August 10, 2023
Completion date	October 10, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05517668` - Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose	Phase 2
Recruiting	`NCT05060289` - A Prognostic Model for Drug-induced Liver Injury in China
Completed	`NCT03092817` - Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)	Phase 3
Completed	`NCT03211208` - Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
Not yet recruiting	`NCT02061826` - Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA)	N/A
Completed	`NCT02182167` - A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis	Phase 2/Phase 3
Completed	`NCT03665402` - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status	N/A
Not yet recruiting	`NCT03091608` - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Granule	N/A
Not yet recruiting	`NCT03091556` - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill.	N/A
Not yet recruiting	`NCT03091218` - Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule.	N/A
Not yet recruiting	`NCT03060252` - Surveillance for Early Liver Injuries Caused by Zhuanggu Guanjie Pill	N/A
Not yet recruiting	`NCT03091244` - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Capsule.	N/A
Completed	`NCT02407964` - A Retrospective Study on Drug Induced Liver Injury in China	N/A
Active, not recruiting	`NCT05144217` - Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo	Phase 2/Phase 3
Completed	`NCT01705041` - Preliminary Evaluation of a Point-Of-Care Liver Function Test	N/A
Recruiting	`NCT02086708` - Ultrasound Method to Measure Fibrosis of the Liver in Children	N/A
Recruiting	`NCT05465642` - Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients
Completed	`NCT01434173` - Risk of Acute Liver Injury in Users of Antimicrobials	N/A
Completed	`NCT05532345` - Discrimination of DILI and AIH by Artificial Intelligence
Completed	`NCT03602703` - Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in DILI Subjects

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms